SIGA Technologies, Inc. Presents Update on ST-246 Development to the World Health Organization

NEW YORK, Nov. 5, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that Dr. Dennis E. Hruby, SIGA’s Chief Scientific Officer, presented SIGA’s progress in developing its lead drug candidate, ST-246, an antiviral for smallpox and other orthopoxviruses, to the World Health Organization (WHO) Advisory Committee on Variola Virus Research on November 4, 2009 in Geneva, Switzerland.

MORE ON THIS TOPIC